Nickel (Ni) oral hyposensitization treatment (NiOHT) is an effective management approach for Ni allergy. No health-related quality of life (HRQoL) data exist for the pre- and post-treatment with NiOHT in systemic nickel allergy syndrome (SNAS). The aims of this study were (a) to explore HRQoL in SNAS patients, (b) to assess changes of HRQoL after 1 year of NiOHT; (c) to evaluate psychological status of patients. SNAS patients completed the Short-Form 36-Item Health Survey and Psychological General Well-Being Index before and 1 week after the end of NiOHT. Moreover, psychological state was assessed with the Minnesota Multiphasic Personality Inventory (MMPI-2). A total of 52 patients self-reported pre- and post-treatment questionnaires. HRQoL was poor at baseline. After 1 year of NiOHT, all outcome measure scores improved by about 20% with respect to baseline data (P < 0.01 for all indices, except depressed mood). Finally, 33 patients performed the MMPI-2. High rates for hypochondriasis and depression were noted. Furthermore, most of the patients had high scores for anxiety, depression, and health concerns. This is the first study showing that NiOHT improves HRQoL of SNAS patients, which can be considered a “personalized medicine” approach.

镍（Ni）口服超敏反应治疗（NiOHT）是治疗Ni过敏的有效方法。对于系统性镍过敏综合征（SNAS）中的NiOHT治疗前后，没有健康相关的生活质量（HRQoL）数据。这项研究的目的是（a）探索SNAS患者的HRQoL，（b）评估NiOHT 1年后HRQoL的变化；（三）评估患者的心理状况。SNAS患者在NiOHT结束前和结束后1周完成了简短的36项健康调查和心理总体健康指数。此外，用明尼苏达州多相人格量表（MMPI-2）评估了心理状态。共有52例患者自我报告了治疗前后的问卷。基线时HRQoL较差。NiOHT一年后， 除抑郁症外，所有指标的P <0.01）。最后，33例患者进行了MMPI-2。注意到软骨病和抑郁症的发病率很高。此外，大多数患者在焦虑，抑郁和健康方面得分较高。这是第一项显示NiOHT改善SNAS患者HRQoL的研究，这可以被视为“个性化药物”方法。